We understand patients. And we understand industry. We bring them together.
read more …Registration now openread more …
Watch the recordingread more …
Read moreread more …
Including patient expertise during the entire product life-cycle is key for truly patient-focused innovative products and services. It is instrumental for successful business. However, how can this be translated into practice? That’s exactly where admedicum comes in.
What?
We help prepare your organization and shape the patient interactions in a way that creates sustainable value for both patients and your business. We provide “fit for purpose” approaches to establishing concepts, tools, advisory groups, networking, coaching and management support where it can help overcome the challenges of a complex relationship between patients and industry.
How?
We provide down-to-earth day-to-day patient-centric business solutions. Together with our clients from the industry, we make patient-industry collaboration happen. We act as advisors, designers and enablers to build trustworthy and effective relationships between patients and industry. We help to merge beneficial impact for patients and value-for-money for industry.
Testimonials
The Sklerodermie e.V. in connection with the scleroderma experts of the DNSS (German Network for Systemic Scleroderma) asked admedicum for support in conducting a survey among more than 1200 scleroderma patients in Germany. The aim was to investigate the extent to which scleroderma patients benefit from the infusion therapy, which is recommended but currently not refinanced and therefore difficult to obtain.
By systematically involving 390 myotonia patients across 18 European countries through the project MYOPATH, admedicum® was instrumental in demonstrating EMA the great need for patient access to Namuscla® (mexiletine). The EMA Committee of Orphan Medicinal Products (COMP) explicitly highlighted the quality of the MYOPATH survey methodology that led to the capture of important information regarding a lack of treatment access resulting in patient harm.
The CDKL5 Research & Family conference, which Philipp was instrumental with in shaping the agenda, was an exceptionally great meeting! I had a chance to talk to many of the families and I know they appreciated these days and loved how much opportunity they had to participate and tell their stories and help shape the field and advance it. This was truly the first patient-centric meeting I’ve ever attended, and that was very much thanks to Philipp‘s vision.
Undisclosed pharma participant on the same conference: „You and Carol-Anne organized the best disease-focused family meeting I ever attended. The interaction and co-collaboration amongst all constituents was extremely beneficial to everyone in attendance. I especially appreciated hearing directly from the caregivers their needs and wants for clinical trials and new medications.“
His vision of a patient centric approach to pharmaceutical development, in particular in rare and orphan diseases, together with the implementation of a concrete series of patient focused events has created a momentum that our company is still benefitting from.
During his time as CEO of Mukoviszidose e.V., the German Cystic Fibrosis (CF) Association (2002 – 2014) and Managing Director of our research affiliate, Mukoviszidose Institut GmbH (2006 – 2015), I got to appreciate Andreas Reimann. I am a father of a son living with CF and I am grateful to what Andreas has contributed to the lives of ...
Philipp possesses all the many skills needed and essential for bringing together patient organizations and their KOLs into the limelight of industry! For more than 30 years, I have promoted genetic diseases and pain awareness as a health professional with a genetic disease and chronic pain.
Rachel interacts with patients and their families with both tact and ease, ensuring that we end up with networks of people engaged and wanting to be involved. She has an ability that I think is rare to find: naturally picking up on peoples non-verbal as well as verbal meanings very quickly.
She is differentiated by her skill at delivery and bringing people together to ensure projects always deliver to time and with much good humour along the way! A true people person, she thrives in organisational situations that others might find tricky, embracing change and challenge herself and ensuring that others benefit and grow ...
Read more
Benefit to clients
We support our clients in providing patient oriented products and services. Economical and profitable products and services contribute to the added value of more patient centric health care ...
About us
admedicum team members have the credibility, expertise, skills and experience to represent both the patient and industry perspective. We have worked on the patient side and in pharma and medtech industry positions. ...
Case-studies
Learn more about our services and see some case studies in areas like „Understanding patient’s needs“, “Patient-focused products and services” and “Patient Engagement Management”.
News
admedicum webinar: Enhancing clinical trial recruitment: successful industry strategies using patient engagement took place on 6 November 2019. We explored how the industry can engage with patients to support clinical trial recruitment rather than just taking the classic method of opening more trial sites.
admedicum in collaboration with the World Alliance of Pituitary Organizations (WAPO), Santhera Pharmaceuticals, and Lupin Pharmaceuticals is pleased to announce a PEGASUS Networking Event on Tuesday 10 December in Leiden from 17:30 to 19:00. All those interested in patient engagement are welcome to join us for a networking event featuring keynote speeches from patient advocates.
A study design that is acceptable to patients may not only be important for the actual relevance of a clinical study, but also for the speed of recruitment and protocol-compliant retention during the study. Patient involvement can therefore directly influence time to market.
Read more … Blog series part 4 of 5: Impact of Patient Engagement on Product Development
